Last reviewed · How we verify
menadione topical lotion
At a glance
| Generic name | menadione topical lotion |
|---|---|
| Sponsor | Mayo Clinic |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Rash maculo-papular
- Pruritus
- Mucositis oral
- Facial pain
- Dehydration
- Erythema multiforme
- Skin and subcutaneous tissue disorders - Other, specify
- Ear pain
- Fatigue
- Pain
- Dry skin
- Pain of skin
Key clinical trials
- Menadione Topical Lotion in Treating Skin Discomfort and Psychological Distress in Patients With Cancer Receiving Panitumumab, Erlotinib Hydrochloride, or Cetuximab (NA)
- Safety, Tolerability and Systemic Absorption of Menadione Topical Lotion for Epidermal-Growth-Factor-Receptor (EGFR) Inhibitor-Associated Rash (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- menadione topical lotion CI brief — competitive landscape report
- menadione topical lotion updates RSS · CI watch RSS
- Mayo Clinic portfolio CI